The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

I continue to reassess the mechanisms of action of blarcamesine and the causes of Alzheimer’s disease itself based on Anavex’s (NASDAQ: AVXL ) long-term open label trial results . Blarcamesine appears to perform no better than Aricept forRetired history instructor. Alzheimer's disease researcher for the past two decades.My goal is to give investors solid advice based on the mechanisms of action of Alzheimer's drugs. This advice is informed by a background in biology (conservation, ecology, evolution, enviro ...